J&J Delivers No Evidence FDA Knew Of "Phantom" Recall - Congressional Staff
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson failed to provide proof that FDA acknowledged the firm's plan for a "phantom" recall of a Motrin product, according to Capitol Hill staff
You may also be interested in...
J&J Settlement With States Not Likely To Be Precedent In OTC Space
J&J's agreement with 42 states and Washington, D.C. is its latest cost from widespread GMP problems that prompted recalls and led to a 2011 FDA consent decree. But the unusual combination of factors suggest more such state actions are unlikely to follow.
J&J Settlement With States Not Likely To Be Precedent In OTC Space
J&J's agreement with 42 states and Washington, D.C. is its latest cost from widespread GMP problems that prompted recalls and led to a 2011 FDA consent decree. But the unusual combination of factors suggest more such state actions are unlikely to follow.
J&J Hears Consent Decree Echoes In Litigation From ‘Silent’ Motrin Recall
J&J intends to appeal to Oregon’s Supreme Court the state appellate court’s decision that the absence of proof of harm to consumers from sales of Motrin 200mg that failed to meet dissolution standards does not preclude unfair trade litigation filed by the state attorney general.